ReviewCytotherapy2020
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
Review in Cytotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed.
- A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count.Journal of translational medicine · 2022Trial
- EF-1α-driven nanobody-based CD19-redirected CAR-T cells retain the antitumor efficacy, antigen-driven expansion, and cytokine secretion of CMV-driven counterparts.Molecular and cellular biochemistry · 2026Article
- Reprogramming innate immunity through viral interference: A double-edged strategy for enhancing and containing gene therapies.Molecular therapy. Nucleic acids · 2026Review
- The status of cell and gene therapy education in medical schools-An international survey.Transfusion · 2026Article
- A decade of innovation in healthcare: Automation, bio-printing and digital twin technologies for personalized therapies.International journal of pharmaceutics: X · 2026Review
- Increasing access to CAR-T therapy: a case study of an academic hospital's alternative innovation model.Orphanet journal of rare diseases · 2026Article
- The 1000eLife · 2026Article
- Programmable nanobody circuits for cell selection.bioRxiv : the preprint server for biology · 2026Article
- Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.Blood advances · 2026Article
- A Physics-Inspired Approach to Improve Oligonucleotide Design and Gene Synthesis.Computational and structural biotechnology journal · 2026Article
- Concurrent MLL-AF4Frontiers in pediatrics · 2026Article
- Glycoengineering CAR-T cells to overcome galectin-3-mediated immunosuppression.Frontiers in immunology · 2026Article
- A universally applicable toolbox for single-molecule quantification of chimeric antigen receptors using linker-resolvedFrontiers in immunology · 2026Article
- Innovations in cancer treatment as novel potential and the myth of personalized vaccines, immunotherapy, CRISPR/Cas9, and bacteriotherapy as promising therapeutic strategies.Discover oncology · 2025Review
- mRNA Vaccines in Cancer Immunotherapy: Recent Advances, Clinical Translation, and Future Perspectives.Current medical science · 2025Review
- Cellular immunotherapies for central nervous system cancers.Neuro-oncology advances · 2025Review
- Synthetic Biology-Based Engineering Living Therapeutics for Antimicrobial Application.Exploration (Beijing, China) · 2025Article
- The Era of Gene Therapy: The Advancement of Lentiviral Vectors and Their Pseudotyping.Viruses · 2025Review
- CAR-T cell therapy for cancer: current challenges and future directions.Signal transduction and targeted therapy · 2025Review
- Atrial fibrillation is associated with increased in-hospitality mortality during Chimeric Antigen Receptor T-cell therapy hospitalizations: a retrospective cohort study in the United States.Cardio-oncology (London, England) · 2025Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Thirty years after initial publications of the concept of a chimeric antigen receptor (CAR), the U.S. Food and Drug Administration (FDA) approved the first anti-CD19 CAR T-cell therapy. Unlike other immunotherapies, such as immune checkpoint inhibitors and bispecific antibodies, CAR T cells are unique as they are "living drugs," that is, gene-edited killer cells that can recognize and kill cancer. During these 30 years of development, the CAR construct, T-cell manufacturing process, and clinical patient management have gone through rounds of failures and successes that drove continuous improvement. Tisagenlecleucel was the first gene therapy to receive approval from the FDA for any indication. The initial approval was for relapsed or refractory (r/r) pediatric and young-adult B-cell acute lymphoblastic leukemia in August 2017 and in May 2018 for adult r/r diffuse large B-cell lymphoma. Here we review the preclinical and clinical development of what began as CART19 at the University of Pennsylvania and later developed into tisagenlecleucel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.